- Zacks•5 hours ago
AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received approval in China.
- Reuters•8 hours ago
Alexion Pharmaceuticals Inc said it named former Baxalta head Ludwig Hantson chief executive officer as the rare-disease drug maker looks to steady the ship following the exit of its top management. David ...
- Investopedia•9 hours ago
Tagrisso becomes first drug from AstraZeneca to be approved under China’s new Priority Review pathway.
AZN.L : Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
|Bid||4,715.00 x 6100|
|Ask||4,985.00 x 13000|
|Day's Range||4,864.50 - 5,053.03|
|52 Week Range||3,680.00 - 5,505.00|
|PE Ratio (TTM)||18.02|
|Dividend & Yield||2.80 (4.68%)|
|1y Target Est||N/A|